This randomized, open-label, parallel-controlled trial investigated the efficacy and safety of needle-free injection (NFI) compared to conventional insulin pen (CIP) in patients with type 2 diabetes mellitus (T2DM) undergoing intensive insulin therapy. The gene discussed is INS; the disease is diabetes mellitus.